Patrick Dentinger of Absorption Systems Selected as a Finalist for Philadelphia Business Journal "Life Sciences CEO of the Year" Award

EXTON, Pa., Sept. 25, 2012 /PRNewswire/ --  Absorption Systems, a global leader in preclinical contract testing of drugs, biologics, and medical devices, is pleased to announce that its President and CEO, Patrick Dentinger, has been selected as a finalist for the Philadelphia Business Journal's "Life Sciences CEO of the Year" award. The awards, co-sponsored by Pennsylvania Bio, will be presented at a ceremony on October 4^th at the Crystal Tea Room in Philadelphia.

"We at Absorption Systems are pleased that our diligence and unwavering commitment to serving the pharmaceutical industry have been recognized by the Business Journal," said Mr. Dentinger. "Having dedicated employees with a shared mission of service excellence for over a decade has  enabled Absorption Systems' stability and growth. On behalf of all of the Absorption Systems employees, I am very proud of our accomplishments, and we all share in the honor of being recognized among so many revered colleagues in the Greater Philadelphia life sciences bionetwork."

Patrick Dentinger and Ismael Hidalgo, Ph.D. co-founded Absorption Systems sixteen years ago and have grown the company steadily. In their case, two heads are better than one, with Mr. Dentinger responsible for all business-related matters while Dr. Hidalgo handles all scientific and technical issues.

Serving more than 250 different customers annually throughout the globe, and over 110 employees based in facilities in Exton, PA, San Diego, CA, and Panama City, Panama, Absorption Systems is a global leader in contract research for the life sciences industry. With the founders' continuing vision and commitment to innovation, the company is poised for an even stronger future.

About Absorption Systems

Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit absorption.com.

SOURCE Absorption Systems